280 related articles for article (PubMed ID: 8896065)
1. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma.
Beaudreuil J; Cohen-Solal M; Doré MX; Vernejoul MC; Bardin T; Celton N; Giraudeaux V; Kuntz D
Rev Rhum Engl Ed; 1996; 63(7-8):502-3. PubMed ID: 8896065
[TBL] [Abstract][Full Text] [Related]
2. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma.
Horiuchi T; Miyachi T; Arai T; Nakamura T; Mori M; Ito H
Horm Metab Res; 1997 Sep; 29(9):469-71. PubMed ID: 9370119
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein mRNA and protein expression in multiple myeloma: a case report.
Schneider HG; Kartsogiannis V; Zhou H; Chou ST; Martin TJ; Grill V
J Bone Miner Res; 1998 Oct; 13(10):1640-3. PubMed ID: 9783553
[TBL] [Abstract][Full Text] [Related]
4. PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.
Niizuma H; Fujii K; Sato A; Fujiwara I; Takeyama J; Imaizumi M
Pediatr Blood Cancer; 2007 Dec; 49(7):990-3. PubMed ID: 16496289
[TBL] [Abstract][Full Text] [Related]
5. Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Kurosawa M; Iwasaki H
Ann Hematol; 2002 Nov; 81(11):668-71. PubMed ID: 12454709
[TBL] [Abstract][Full Text] [Related]
6. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
7. [High PTHrP level induced hypercalcemia and acute renal failure in a multiple myeloma patient].
Saito O; Kurosu M; Ando Y; Kusano E; Asano Y
Nihon Jinzo Gakkai Shi; 2000 Jan; 42(1):41-6. PubMed ID: 10737013
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide.
Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A
J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119
[TBL] [Abstract][Full Text] [Related]
9. Lymphoma with hypercalcemia.
Walker IR
Can Med Assoc J; 1974 Nov; 111(9):928-30. PubMed ID: 4608255
[TBL] [Abstract][Full Text] [Related]
10. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
[TBL] [Abstract][Full Text] [Related]
11. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of cancer-induced hypercalcemia.
Rosol TJ; Capen CC
Lab Invest; 1992 Dec; 67(6):680-702. PubMed ID: 1460860
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma.
Zeimer H; Firkin F; Grill V; Slavin J; Zhou H; Martin TJ
J Pathol; 2000 Nov; 192(3):336-41. PubMed ID: 11054717
[TBL] [Abstract][Full Text] [Related]
14. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
16. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
Reagan P; Pani A; Rosner MH
Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
[TBL] [Abstract][Full Text] [Related]
17. Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy.
Chattopadhyay N
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E761-70. PubMed ID: 16603723
[TBL] [Abstract][Full Text] [Related]
18. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Shimizu H; Monden T; Tomotsune T; Nakatani Y; Domeki N; Matsumura M; Jojima T; Kawagoe Y; Kasai K
Intern Med; 2011; 50(24):2993-6. PubMed ID: 22185991
[TBL] [Abstract][Full Text] [Related]
19. Non-secretory multiple myeloma with hypercalcemic acute renal failure.
Prakash MS; Baliga KV; Singh AP; Mishra DK
J Assoc Physicians India; 2002 Oct; 50():1330-1. PubMed ID: 12568228
[No Abstract] [Full Text] [Related]
20. Frequency of hypercalcemia in patients of multiple myeloma in Karachi.
Mansoor S; Siddiqui I; Adil S; Kakapeto GN; Fatmi Z
J Coll Physicians Surg Pak; 2005 Jul; 15(7):409-12. PubMed ID: 16197869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
